AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35208561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 71
Study 35208561 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 71
Study 32890574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion group (CMF) - at least 10 mL of cow's milk formula daily between 1 and 2 months of age
Number of subjects: 491
Study 32890574 — intervention group
Group type: COMPARATOR
Intervention: Avoidance group (no CMF) - avoid cow's milk formula and supplement with soy formula as needed
Number of subjects: 491
Study 35416566 — intervention group
Group type: COMPARATOR
Intervention: Control arm of the ORBIT-Trial (pre-COVID group, n=44)
Number of subjects: 112
Study 35416566 — intervention group
Group type: COMPARATOR
Intervention: Control arm of the ORBIT-Trial (during-COVID group, n=47)
Number of subjects: 112
Study 34968929 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio as an assessment tool
Number of subjects: 15
Study 33438846 — intervention group
Group type: COMPARATOR
Intervention: Custodiol cardioplegia (CC)
Number of subjects: 30
Study 33438846 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BC)
Number of subjects: 30
Study 36484665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-translucency zirconia (ZC)
Number of subjects: 71
Study 36484665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-translucency zirconia with a partial buccal veneer (ZC-V)
Number of subjects: 71
Study 36484665 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate glass-ceramic (LDS)
Number of subjects: 71
Study 36484665 — intervention group
Group type: EXPERIMENTAL
Intervention: All crown types
Number of subjects: 71
Study 34514949 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-guided microwave ablation (MWA)
Number of subjects: 304
Study 32912308 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Together whole-school intervention with staff training in restorative practice, a social and emotional learning curriculum, and an external facilitator.
Number of subjects: 0
Study 35974296 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation IPL (Eyesis)
Number of subjects: 132
Study 35974296 — intervention group
Group type: COMPARATOR
Intervention: Traditional IPL (E-Eye)
Number of subjects: 132
Study 32102909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes (various nicotine contents)
Number of subjects: 70
Study 32102909 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes with increased tar yield
Number of subjects: 70
Study 32102909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 33572368 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus EPA (2 g/d)
Number of subjects: 72
Study 33572368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat germ oil)
Number of subjects: 72
Study 33032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual demonstration of successful PCI (printout picture of coronary angiogram before and after PCI)
Number of subjects: 144
Study 33032655 — intervention group
Group type: COMPARATOR
Intervention: Common written procedural report on the procedure (Control group)
Number of subjects: 144
Study 33032655 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual demonstration of successful PCI
Number of subjects: 144
Study 33705210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (registry-derived patients)
Number of subjects: 2008
Study 34941209 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided ligation
Number of subjects: 120
Study 34941209 — intervention group
Group type: COMPARATOR
Intervention: Ligation without ultrasound
Number of subjects: 120
Study 36152456 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (reward for accurate performance estimates)
Number of subjects: 193
Study 36152456 — intervention group
Group type: COMPARATOR
Intervention: No-incentive control condition
Number of subjects: 193
Study 32839125 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced deliberation (n = 437)
Number of subjects: 881
Study 32839125 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced deliberation (n = 444)
Number of subjects: 881
Study 32839125 — intervention group
Group type: EXPERIMENTAL
Intervention: All nurses
Number of subjects: 881
Study 34120755 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐ECG
Number of subjects: 1996
Study 32078356 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast in the Classroom (BIC) initiative
Number of subjects: 1362
Study 32078356 — intervention group
Group type: COMPARATOR
Intervention: Control schools (breakfast in cafeteria before school)
Number of subjects: 1362
Study 35313978 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 2 mg/kg administered at weeks 0 and 4, then every 8 weeks through week 100 (RA) or week 52 (PsA, AS)
Number of subjects: 1279
Study 35313978 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (all treated patients)
Number of subjects: 1279
Study 35313978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1279
Study 35313978 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant methotrexate
Number of subjects: 1279
Study 35313978 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant low-dose oral corticosteroids
Number of subjects: 1279
Study 35313978 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 1279
Study 33792669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4304
Study 33792669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 32457995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime administered by continuous infusion
Number of subjects: 108
Study 32457995 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime administered by intermittent infusion
Number of subjects: 108
Study 32457995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime in CF patients
Number of subjects: 108
Study 32457995 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime in non-CF patients
Number of subjects: 108
Study 36038883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high-intensity smoking cessation intervention starting 4 weeks before surgery
Number of subjects: 251
Study 36038883 — intervention group
Group type: COMPARATOR
Intervention: Advice-only group (control group)
Number of subjects: 251
Study 33296943 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 prophylaxis (damoctocog alfa pegol)
Number of subjects: 80
Study 33296943 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 prophylaxis
Number of subjects: 80
Study 35394149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial administration of autologous neonatal c-kit+ cardiac-derived progenitor cells (nCPCs)
Number of subjects: 32
Study 35394149 — intervention group
Group type: COMPARATOR
Intervention: Randomized, double-blinded administration of nCPCs
Number of subjects: 32
Study 33619999 — intervention group
Group type: EXPERIMENTAL
Intervention: GI biopsy result of normal mucosa
Number of subjects: 1050105
Study 33619999 — intervention group
Group type: EXPERIMENTAL
Intervention: GI biopsy result of non-specific inflammation
Number of subjects: 1050105
Study 33619999 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without GI biopsy)
Number of subjects: 1050105
Study 32342703 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up (RFU)
Number of subjects: 1274
Study 32342703 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-office follow-up
Number of subjects: 1274
Study 34399009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain ratings provided by a single person (group 3)
Number of subjects: 0
Study 34399009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain ratings provided by a group of people (group 4)
Number of subjects: 0
Study 34399009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain ratings presented to participants (group 1 and 2)
Number of subjects: 0
Study 34399009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 0
Study 34900170 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime plus SinaAmpholeish (topical nano-liposomal amphotericin B 0.4%)
Number of subjects: 130
Study 34900170 — intervention group
Group type: COMPARATOR
Intervention: Glucantime (intralesional injections)
Number of subjects: 130
Study 36476743 — intervention group
Group type: EXPERIMENTAL
Intervention: Text + Pictogram HWLs
Number of subjects: 1755
Study 36476743 — intervention group
Group type: EXPERIMENTAL
Intervention: Text + Photograph HWLs
Number of subjects: 1755
Study 36476743 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-Only HWLs
Number of subjects: 1755
Study 36476743 — intervention group
Group type: COMPARATOR
Intervention: DrinkWise control
Number of subjects: 1755
Study 36476743 — intervention group
Group type: COMPARATOR
Intervention: No HWL control
Number of subjects: 1755
Study 33761143 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.91 g of red clover extract (containing 8 mg formononetin and 1.8 mg biochanin A)
Number of subjects: 36
Study 33761143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32192539 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PM+/enhanced care as usual (Group PM+/E-CAU)
Number of subjects: 380
Study 32192539 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care as usual (E-CAU)
Number of subjects: 380
Study 32653904 — intervention group
Group type: EXPERIMENTAL
Intervention: AKB‐9778
Number of subjects: 0
Study 32653904 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoda1 (PIEZO1 activator)
Number of subjects: 0
Study 32653904 — intervention group
Group type: EXPERIMENTAL
Intervention: VE‐PTP inhibition
Number of subjects: 0
Study 35796684 — intervention group
Group type: EXPERIMENTAL
Intervention: Miamo Renewal Peel Serum (ELPA25™) applied three times a week for 8 weeks
Number of subjects: 30
Study 35796684 — intervention group
Group type: COMPARATOR
Intervention: Mandelic acid serum (control) applied three times a week for 8 weeks
Number of subjects: 30
Study 35796684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) applied three times a week for 8 weeks
Number of subjects: 30
Study 33685395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation volume-guaranteed (PCV-VG)
Number of subjects: 80
Study 33685395 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 80
Study 35995103 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g of tobacco)
Number of subjects: 50
Study 35995103 — intervention group
Group type: COMPARATOR
Intervention: Normal Nicotine Content (NNC) cigarettes (15.8 mg/g of tobacco)
Number of subjects: 50
Study 35995103 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquid with low nicotine (0.3%)
Number of subjects: 50
Study 35995103 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquid with moderate nicotine (1.8%)
Number of subjects: 50
Study 35995103 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids available in various flavors (tobacco, fruit, dessert, mint)
Number of subjects: 50
Study 35995103 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liquids available in tobacco flavors
Number of subjects: 50
Study 33863850 — intervention group
Group type: EXPERIMENTAL
Intervention: MotionWatch 8 (MW8) triaxial actigraphy device
Number of subjects: 321
Study 33555332 — intervention group
Group type: EXPERIMENTAL
Intervention: Device monitoring and feedback during intervention period
Number of subjects: 97
Study 33555332 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no device)
Number of subjects: 97
Study 33555332 — intervention group
Group type: COMPARATOR
Intervention: Transition (device monitoring without feedback)
Number of subjects: 97
Study 32367010 — intervention group
Group type: EXPERIMENTAL
Intervention: CK advertisement
Number of subjects: 400
Study 32367010 — intervention group
Group type: EXPERIMENTAL
Intervention: CK advertisement with disclaimers
Number of subjects: 400
Study 32367010 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific information from peer-reviewed literature
Number of subjects: 400
Study 32367010 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 35172043 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet, fasted (reference, dosed twice)
Number of subjects: 30
Study 35172043 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet, 30 minutes after a high-fat meal (test 1)
Number of subjects: 30
Study 35172043 — intervention group
Group type: EXPERIMENTAL
Intervention: Old tablet, fasted (test 2)
Number of subjects: 30
Study 35172043 — intervention group
Group type: EXPERIMENTAL
Intervention: Navtemadlin (overall)
Number of subjects: 30
Study 32675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 64
Study 32675585 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS pain score at 4 weeks
Number of subjects: 64
Study 32675585 — intervention group
Group type: EXPERIMENTAL
Intervention: VASratio (VAS pain score at 4 weeks divided by VAS pain score at 2 weeks)
Number of subjects: 64
Study 32675585 — intervention group
Group type: EXPERIMENTAL
Intervention: VASratio above 0.6
Number of subjects: 64
Study 32912974 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT) plus usual care (UC)
Number of subjects: 0
Study 32912974 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 35276867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) supplementation
Number of subjects: 16
Study 35276867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33649520 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 50 μg
Number of subjects: 279
Study 33649520 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg
Number of subjects: 279
Study 35074878 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cash gift group (monthly unconditional cash gift)
Number of subjects: 1000
Study 35074878 — intervention group
Group type: COMPARATOR
Intervention: Low-cash gift group (nominal monthly unconditional cash gift)
Number of subjects: 1000
Study 34593725 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene knee sleeve (WS)
Number of subjects: 20
Study 34593725 — intervention group
Group type: COMPARATOR
Intervention: No knee sleeve (NS)
Number of subjects: 20
Study 35931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (PB) with 2 g of PBF1 added to colostrum and 1 g of PBF2 added to milk 3 times per week until weaning
Number of subjects: 232
Study 35931480 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR) receiving no probiotics
Number of subjects: 232
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2-step 2-year progression
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 3-step 2-year progression
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of neovascular (NV) AMD
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of central geographic atrophy (CGA)
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of any geographic atrophy (GA)
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2-line BCVA loss
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 3-line BCVA loss
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2-step 2-year progression and subsequent development of NV AMD
Number of subjects: 3868
Study 32271358 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 2-step 2-year progression and subsequent development of CGA
Number of subjects: 3868
Study 35674649 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Comprehensive Rehabilitation (ICR)
Number of subjects: 40
Study 35674649 — intervention group
Group type: COMPARATOR
Intervention: Aquatic Training
Number of subjects: 40
Study 34003963 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 0
Study 34003963 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 0
Study 34003963 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (treatment agnostic)
Number of subjects: 0
Study 32429069 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational SMS intervention on nutrition and physical activity during pregnancy, one text message per week for eighteen weeks.
Number of subjects: 83
Study 32429069 — intervention group
Group type: COMPARATOR
Intervention: Control group received SMS about general health topics during pregnancy, one text message per week for eighteen weeks.
Number of subjects: 83
Study 35832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care based on the combination of medical care and nursing (Observation Group)
Number of subjects: 96
Study 34695679 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered early intervention
Number of subjects: 141
Study 34695679 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 32468992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model (FDM) intervention
Number of subjects: 90
Study 32468992 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling technique
Number of subjects: 90
Study 32468992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 35777616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid pegylated liposomal doxorubicin (PLD) hydrochloride injection
Number of subjects: 50
Study 35777616 — intervention group
Group type: COMPARATOR
Intervention: Caelyx®
Number of subjects: 50
Study 34324065 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted PD-1/PD-L1
Number of subjects: 3301
Study 34324065 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PD-1 levels
Number of subjects: 3301
Study 34324065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower PD-L1 levels
Number of subjects: 3301
Study 34324065 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted PD-L1
Number of subjects: 3301
Study 32566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 0
Study 32566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular options for hostile neck anatomy (fenestrated endografts, chimney grafts, endoanchors)
Number of subjects: 0
Study 32566971 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular and long-term imaging and clinical surveillance
Number of subjects: 0
Study 32566971 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR technology
Number of subjects: 0
Study 35926845 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding vibration during varied high-intensity interval training (HIIT) sessions
Number of subjects: 12
Study 33620499 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructivist teaching method (CTM)
Number of subjects: 122
Study 33620499 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 122
Study 32525562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) for 12 weeks
Number of subjects: 16
Study 32525562 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 16
Study 35311993 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist response style
Number of subjects: 31
Study 35311993 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermometer response style
Number of subjects: 31
Study 35311993 — intervention group
Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 31
Study 32003645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol-10 (300 mg/day)
Number of subjects: 16
Study 32003645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32988951 — intervention group
Group type: EXPERIMENTAL
Intervention: MyndMove neuromodulation therapy
Number of subjects: 60
Study 32988951 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 60
Study 35191232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 56
Study 35191232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33828260 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-based interventions
Number of subjects: 142
Study 33828260 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 142
Study 32272458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at abductor hallucis motor-point with 150 bursts at varying frequencies (8-32 Hz) and stimulation currents (10%, 20%, and 30% higher than m-wave stimulation current)
Number of subjects: 15
Study 32272458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation protocols (protocols 1-3) with incremental changes in stimulation frequency
Number of subjects: 15
Study 32272458 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort's test-retest reliability
Number of subjects: 15
Study 37030179 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed silicone small bowel simulator (8 practice sessions at home)
Number of subjects: 16
Study 37030179 — intervention group
Group type: COMPARATOR
Intervention: No hands-on practice (control group)
Number of subjects: 16
Study 37030179 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed silicone small bowel simulator (posttest and retention-transfer test)
Number of subjects: 16
Study 34481768 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based screening technology using facial photographs
Number of subjects: 2800
Study 35881397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized plasma transfusion
Number of subjects: 150
Study 35881397 — intervention group
Group type: COMPARATOR
Intervention: Standard care with normal saline infusion (control)
Number of subjects: 150